Market Place
Sourcing Support
Sobi`s FDA Acceptance of Avatrombopag NDA for Pediatric ITP
12 Dec 2024 //
GLOBENEWSWIRE
Gyre Therapeutics Announces NMPA Approval Of Avatrombopag Maleate Tablets
02 Jul 2024 //
GLOBENEWSWIRE
Health Canada Approves DOPTELET for Two Indications in Thrombocytopenia
06 Nov 2023 //
GLOBENEWSWIRE
Doptelet® (avatrombopag) receives positive opinion from CHMP ITP
11 Dec 2020 //
PRNEWSWIRE
Swedish Orphan`s avatrombopag flunks late-stage study in chemo-induced
09 Oct 2020 //
SEEKINGALPHA
NICE pushes Doptelet for pre-surgery liver disease treatment
06 Mar 2020 //
PHARMA TIMES
Dova Granted Orphan Drug Designation for Avatrombopag
13 Jan 2020 //
PR NEWSWIRE
Additional Analyses From Phase 3 study With Doptelet ® (avatrombopag)
09 Dec 2019 //
PR NEWSWIRE
Sobi finds another fit for its dealmaking strategy
01 Oct 2019 //
BIOPHARMADIVE
Can Dova take on Novartis? With its 2nd Doptelet nod and a price cut, maybe so
29 Jun 2019 //
FIERCE PHARMA
Cosmo to give Bausch Health a run for its money with FDA nod for Xifaxan rival
21 Nov 2018 //
FIERCE PHARMA
Dova picked up its newly approved drug castoff at a low price
31 May 2018 //
ENDPTS
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.